Beruflich Dokumente
Kultur Dokumente
IDSA GUIDELINE
These guidelines are intended for use by infectious disease specialists, orthopedic surgeons, neurosurgeons, ra-
diologists, and other healthcare professionals who care for patients with native vertebral osteomyelitis (NVO).
They include evidence and opinion-based recommendations for the diagnosis and management of patients with
NVO treated with antimicrobial therapy, with or without surgical intervention.
Keywords. spondylodiscitis; osteomyelitis; Staphylococcus aureus; spine infection; discitis.
I. When Should the Diagnosis of NVO Be Considered? III. When Should an Image-Guided Aspiration Biopsy or
Recommendations Additional Workup Be Performed in Patients With NVO?
1. Clinicians should suspect the diagnosis of NVO in patients Recommendations
with new or worsening back or neck pain and fever (strong, 14. We recommend an image-guided aspiration biopsy in pa-
low). tients with suspected NVO (based on clinical, laboratory, and
2. Clinicians should suspect the diagnosis of NVO in patients imaging studies) when a microbiologic diagnosis for a known
with new or worsening back or neck pain and elevated ESR associated organism (S. aureus, Staphylococcus lugdunensis,
or CRP (strong, low). and Brucella species) has not been established by blood cul-
3. Clinicians should suspect the diagnosis of NVO in patients tures or serologic tests (strong, low).
with new or worsening back or neck pain and bloodstream 15. We advise against performing an image-guided aspiration bi-
infection or infective endocarditis (strong, low). opsy in patients with S. aureus, S. lugdunensis, or Brucella spe-
4. Clinicians may consider the diagnosis of NVO in patients cies bloodstream infection suspected of having NVO based on
who present with fever and new neurologic symptoms with clinical, laboratory, and imaging studies (strong, low).
or without back pain (weak, low). 16. We advise against performing an image-guided aspiration
5. Clinicians may consider the diagnosis of NVO in patients biopsy in patients with suspected subacute NVO (high en-
who present with new localized neck or back pain, following demic setting) and strongly positive Brucella serology
a recent episode of Staphylococcus aureus bloodstream infec- (strong, low).
tion (weak, low).
IV. How Long Should Antimicrobial Therapy Be Withheld Prior to
an Image-Guided Diagnostic Aspiration Biopsy in Patients With
II. What Is the Appropriate Diagnostic Evaluation of Patients With Suspected NVO?
Suspected NVO? Recommendations
Recommendations 17. In patients with neurologic compromise with or without
6. We recommend performing a pertinent medical and motor/ impending sepsis or hemodynamic instability, we recom-
sensory neurologic examination in patients with suspected mend immediate surgical intervention and initiation of em-
NVO (strong, low). piric antimicrobial therapy (strong, low).
2 • CID • Berbari et al
Table 1. Strength of Recommendations and Quality of the Evidence
V. When Is It Appropriate to Send Fungal, Mycobacterial, or risk factors, or characteristic radiologic clues are present
Brucellar Cultures or Other Specialized Testing Following an (weak, low).
Image-Guided Aspiration Biopsy in Patients With Suspected NVO? 19. We suggest the addition of fungal and mycobacterial cul-
Recommendations tures and bacterial nucleic acid amplification testing to ap-
18. We suggest the addition of fungal, mycobacterial, or bru- propriately stored specimens if aerobic and anaerobic
cellar cultures on image-guided biopsy and aspiration speci- bacterial cultures reveal no growth in patients with suspected
mens in patients with suspected NVO if epidemiologic, host NVO (weak, low).
4 • CID • Berbari et al
tissue findings in patients with NVO and suspected treat- instances, the panel has made recommendations based on ex-
ment failure (strong, low). pert opinion only, realizing that the amount of data to support
37. In patients with NVO and clinical and radiographic a specific recommendation is limited. The panel acknowledges
evidence of treatment failure, we suggest obtaining additional that there are diverse practice patterns that seem to be equally
tissue samples for microbiologic (bacteria, fungal, and myco- effective in the management of NVO. However, an essential ad-
bacterial) and histopathologic examination, either by image- vantage of this specific therapeutic approach is the strong col-
guided aspiration biopsy or through surgical sampling (weak, laboration between all involved medical and surgical specialists
very low). (eg, orthopedic surgeons, radiologists, neurosurgeons, infec-
38. In patients with NVO and clinical and radiographic evi- tious disease specialists, pain specialists). It is anticipated that
dence of treatment failure, we suggest consultation with a adoption of these guidelines may help reduce morbidity, mor-
spine surgeon and an infectious disease physician (weak, tality, and the costs associated with the management of NVO.
very low). The panel acknowledges that not all medical institutions will have
the adequate resources to implement all of the recommendations
in these guidelines. Proper referral may be needed. The panel
INTRODUCTION
elected not to address patients with spinal implant–associated in-
fections, patients with postprocedure infections, and patients
The incidence of NVO varies by country, age of the population
with epidural abscess without associated NVO. The management
studied, and whether endemic infections are included. In one
of these entities may differ from the management of patients with
study from France, the overall incidence of NVO was 2.4 per
6 • CID • Berbari et al
updated guidelines based on an examination of current litera- with mycobacterial, brucellar, or fungal NVO and may be
ture. If necessary, the entire panel will reconvene to discuss masked in patients taking analgesics with antipyretic effects
potential changes. When appropriate, the panel will recom- [31–35]. In patients with insidious chronic back pain or in pa-
mend full revision of the guidelines to the IDSA SPGC and tients with paraplegia, the diagnosis can be overlooked due to
the Board for review and approval. other, more common causes of back or neck pain. The pain is
typically localized to the infected disc space area and is exacer-
bated by physical activity or percussion to the affected area. Pain
RECOMMENDATIONS FOR CLINICAL
may radiate to the abdomen, hip, leg, scrotum, groin, or perine-
DIAGNOSTICS
um [36]. Paravertebral muscle tenderness and spasm, and lim-
I. When Should the Diagnosis of NVO Be Considered?
itation of spine movement, are the predominant physical
Recommendations examination findings. In a series of 253 patients with bacterial
1. Clinicians should suspect the diagnosis of NVO in patients NVO, 43% had epidural or paravertebral extension [6]. Spinal
with new or worsening back or neck pain and fever (strong, cord or nerve root compression and meningitis may occur.
low). Neurologic signs and symptoms are more commonly encoun-
2. Clinicians should suspect the diagnosis of NVO in patients tered in patients with cervical or thoracic involvement.
with new or worsening back or neck pain and elevated ESR An elevated ESR or CRP result in patients with back pain,
or CRP (strong, low). though not specific, has a sensitivity that can range from 94%
3. Clinicians should suspect the diagnosis of NVO in patients to 100% [37, 38]. These inflammatory markers are often used to
8 • CID • Berbari et al
without a paraspinal mass or mixed soft tissue fluid collection, inflammation, granuloma formation, and malignancy. In addition
or, less commonly, (4) spondylitis without disc involvement to bacterial cultures, mycobacterial, brucellar, and fungal cultures
[68]. An interferon-γ release assay has been shown to have a should be obtained in cases of subacute and chronic NVO [52].
higher sensitivity than PPD, especially in patients with altered The main microbiologic etiology of bacterial NVO is S. aureus
immunity [69]. A recent study found a higher sensitivity and [9]. Blood cultures can be positive in up to 50% of cases of
specificity of enzyme-linked immunospot assay compared S. aureus NVO. A positive blood culture for S. aureus obviates
with PPD in the diagnosis of tuberculous NVO (sensitivity, the need for an image-guided aspiration specimen in patients
82.8% vs 58.6% and specificity, 81.3% vs 59.4%, respectively) with clinical, laboratory, and radiologic findings suggestive of
[70]. NVO [1, 10, 77]. In a national study from Denmark of 8739 pa-
tients with S. aureus bloodstream infection, an incidence of 6% of
associated NVO was found in patients aged > 50 years in whom
III. When Should an Image-Guided Aspiration Biopsy or
Additional Workup Be Performed in Patients With NVO?
no obvious entry source was identified [77]. Staphylococcus lugdu-
Recommendations nensis has been associated with deep-seated infections and can
14. We recommend an image-guided aspiration biopsy in all often behave like S. aureus [78, 79]. A persistently positive blood
patients with suspected NVO (based on clinical, laboratory, culture for this organism in NVO may obviate the need for an
and imaging studies) when a microbiologic diagnosis for a image-guided biopsy. A sustained bloodstream infection with
known associated organism (S. aureus, Staphylococcus lugdu- other coagulase-negative staphylococci in patients with suspected
nensis, and Brucella species) has not been established by NVO receiving chronic hemodialysis or in patients with infected
10 • CID • Berbari et al
with brucellar NVO tend to have multilevel involvement and VI. When Is It Appropriate to Send the Specimens for Pathologic
are less likely to have paravertebral collections [93]. Nontuber- Examination Following an Image-Guided Aspiration Biopsy in
culous mycobacteria are rare causes of NVO but have been Patients With Suspected NVO?
described in immunocompromised patients including those Recommendation
who have systemic lupus erythematous on receiving steroids, 20. If adequate tissue can be safely obtained, pathology speci-
AIDS, interferon receptor defects, carcinoma, and chronic mens should be sent from all patients to help confirm a diag-
granulomatous disease (CGD) [101]. Intravesicular bacillus nosis of NVO and to help guide further diagnostic testing,
Calmette-Guerin (BCG) therapy used to treat carcinoma in especially in the setting of negative cultures (strong, low).
situ of the bladder has also been associated with BCG NVO.
In patients with intractable back pain, a history of bladder Evidence Summary
cancer treated with intravesical BCG instillation should be The differential diagnosis of a patient with back pain and an
elucidated [102]. MRI abnormality includes NVO, neoplasm, acute disc hernia-
Fungal NVO is rare and is most commonly seen in immuno- tion with disc space collapse, and osteoporosis-associated verte-
compromised patients. Fungal pathogens account for 0.5%– bral collapse (vertebral compression fracture). Most patients
1.6% of the cases of NVO [95]. Risk factors for these pathogens with bacterial NVO will have inflammatory changes in the
are significant immunosuppression including steroid use, pres- disc space with associated end-plate changes of the 2 adjacent
ence of a long-term indwelling venous catheter, IVDA, neutro- vertebral bodies. Exceptions, however are seen, especially in
penia, and CGD [95]. early tuberculous NVO where disease may be limited to the ver-
12 • CID • Berbari et al
antifungal and antimycobacterial therapy is not appropriate in coverage of aerobic gram-negative bacilli (Table 2). Selected reg-
most situations. Empiric antimicrobial therapy is dependent on imens that were discussed might include vancomycin in combi-
the host, the clinical situation, and the epidemiologic risk, as nation with ciprofloxacin, vancomycin in combination with
well as the local historical in vitro susceptibility data. Several em- cefepime, or vancomycin in combination with a carbapenem.
piric antimicrobial regimens were suggested by the panel mem- The panel was not in favor of routine use of empiric regimens
bers. This might include regimens that have coverage against that include coverage against anaerobes or fungal, brucellar, or
staphylococci, including oxacillin-resistant strains, as well as the mycobacterial organisms.
Table 2. Parenteral Antimicrobial Treatment of Common Microorganisms Causing Native Vertebral Osteomyelitis
14 • CID • Berbari et al
Table 3. Selected Oral Antibacterial Agents With Excellent Oral A number of surgical management strategies have been dis-
Bioavailability Commonly Used to Treat Patients With Native cussed in the literature. None of these approaches have been
Vertebral Osteomyelitis subjected to randomized clinical trials. These options include
an anterior or posterior approach, single vs staged surgery,
Oral Agents Comments
with or without instrumentation [139].
Metronidazole 500 mg PO Can be used in the intital course of NVO In a cohort of disc space infection by McHenry et al that in-
tid to qid due to Bacteroides species and other
susceptible anaerobes. cluded some patients with spinal implant–associated infections,
Moxifloxacin 400 mg PO Is not recommended for use in patients 109 of 253 patients underwent surgical management. The most
once daily with staphylococcal NVO, but may be frequent indications for surgery in this cohort were drainage of
used in patients with NVO due to
Enterobacteriaceae and other abscesses (85 patients); relief of compression of the spinal cord,
susceptible aerobic gram-negative cauda equina, or nerve roots (48 patients); and spinal stabiliza-
organisms.
tion (32 patients). The outcome was favorable in 86 of 109 pa-
Linezolid 600 mg PO bid Can be used in the intital course of NVO
due to oxacillin-resistant staphylocci tients (79%). Of the 48 patients with neurologic impairment
when first-line agents cannot be used. who underwent surgical treatment via an anterior or posterior
Levofloxacin 500–750 mg Is not recommended for use in patients approach, the outcome was favorable for 33 (69%) [6].
PO once daily with staphylococcal NVO as
monotherapy but may be used in Valancius et al reviewed the management strategies in 196
patients with NVO due to patients with NVO seen in a single institution over a 10-year
Enterobacteriaceae and other
susceptible aerobic gram-negative period, of whom 100 patients required surgical intervention
16 • CID • Berbari et al
tissue findings in patients with NVO and suspected treat- image-guided aspiration biopsy to definitively establish the di-
ment failure (strong, low). agnosis of treatment failure and confirm microbiologic etiology.
37. In patients with NVO and clinical and radiographic evidence For culture-negative NVO patients with suspected treatment
of treatment failure, we suggest obtaining additional tissue sam- failure, we recommend undertaking additional attempts to iso-
ples for microbiologic (bacteria, fungal, and mycobacterial) and late an etiologic pathogen. This should include obtaining tissue
histopathologic examination, either by image-guided aspiration for histopathology; aerobic and anaerobic bacterial cultures; and
biopsy or through surgical sampling (weak, very low). fungal, brucellar, and mycobacterial cultures. In select circum-
38. In patients with NVO and clinical and radiographic evi- stances, serologic assays for uncommon causes of NVO should
dence of treatment failure, we suggest consultation with a be considered as well.
spine surgeon and an infectious disease physician (weak,
very low).
RESEARCH GAPS
Evidence Summary
One of the steps in developing a rational clinical research agen-
The most consistent finding in NVO treatment failure is persis-
da in NVO is the identification of evidence-based gaps in infor-
tent or recurrent severe back pain [6]. However, many patients
mation. The process of guideline development outlined above
with NVO otherwise thought to be cured report persistent pain
serves as a natural means by which such gaps are identified.
at the time of last follow-up [6, 146, 147]. Patients with persistent
Clinical questions identified by the NVO guideline authors
or progressive pain, systemic symptoms of infection, undrained
18 • CID • Berbari et al
31. Oztekin O, Calli C, Adibelli Z, Kitis O, Eren C, Altinok T. Brucellar 54. Sapico FL, Montgomerie JZ. Vertebral osteomyelitis. Infect Dis Clin
spondylodiscitis: magnetic resonance imaging features with conven- North Am 1990; 4:539–50.
tional sequences and diffusion-weighted imaging. Radiol Med 2010; 55. Theodoros K, Sotirios T. Successful treatment of azole-resistant Can-
115:794–803. dida spondylodiscitis with high-dose caspofungin monotherapy.
32. Goertz CE, Frasca S Jr, Bohach GA, et al. Brucella sp. vertebral osteo- Rheumatol Int 2012; 32:2957–8.
myelitis with intercurrent fatal Staphylococcus aureus toxigenic enter- 56. Joshi TN. Candida albicans spondylodiscitis in an immunocompetent
itis in a bottlenose dolphin (Tursiops truncatus). J Vet Diagn Invest patient. J Neurosci Rural Pract 2012; 3:221–2.
2011; 23:845–51. 57. Jorge VC, Cardoso C, Noronha C, Simoes J, Riso N, Vaz Riscado M.
33. Kraniotis P, Marangos M, Lekkou A, Romanos O, Solomou E. Brucel- Fungal spondylodiscitis in a non-immunocompromised patient. BMJ
losis presenting as piriformis myositis: a case report. J Med Case Re- Case Rep 2012; doi:10.1136/bcr.12.2011.5337.
ports 2011; 5:125. 58. Werner BC, Hogan MV, Shen FH. Candida lusitaniae discitis after dis-
34. Mrabet D, Mizouni H, Khiari H, et al. Brucellar spondylodiscitis af- cogram in an immunocompetent patient. Spine J 2011; 11:e1–6.
fecting non-contiguous spine levels. BMJ Case Rep 2011; 2011. 59. Rachapalli SM, Malaiya R, Mohd TA, Hughes RA. Successful treat-
35. Song KJ, Yoon SJ, Lee KB. Cervical spinal brucellosis with epidural ab- ment of Candida discitis with 5-flucytosine and fluconazole. Rheuma-
scess causing neurologic deficit with negative serologic tests. World tol Int 2010; 30:1543–4.
Neurosurg 2012; 78:375.e15–9. 60. Cho K, Lee SH, Kim ES, Eoh W. Candida parapsilosis spondylodiscitis
36. Wong-Chung JK, Naseeb SA, Kaneker SG, Aradi AJ. Anterior disc after lumbar discectomy. J Korean Neurosurg Soc 2010; 47:295–7.
protrusion as a cause for abdominal symptoms in childhood discitis. 61. Moon HH, Kim JH, Moon BG, Kim JS. Cervical spondylodiscitis
A case report. Spine 1999; 24:918–20. caused by Candida albicans in non-immunocompromised patient. J
37. Siemionow K, Steinmetz M, Bell G, Ilaslan H, McLain RF. Identifying Korean Neurosurg Soc 2008; 43:45–7.
serious causes of back pain: cancer, infection, fracture. Cleve Clin J 62. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis:
Med 2008; 75:557–66. clinical practice guidelines of the Infectious Diseases Society of Amer-
38. Jensen AG, Espersen F, Skinhoj P, Frimodt-Moller N. Bacteremic ica. Clin Infect Dis 2008; 46:327–60.
20 • CID • Berbari et al
resistant Staphylococcus aureus infections in adults and children: exec- 139. Chen WH, Jiang LS, Dai LY. Surgical treatment of pyogenic vertebral
utive summary. Clin Infect Dis 2011; 52:285–92. osteomyelitis with spinal instrumentation. Eur Spine J 2007; 16:
124. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diag- 1307–16.
nosis, antimicrobial therapy, and management of complications: a 140. Valancius K, Hansen ES, Hoy K, Helmig P, Niedermann B, Bunger C.
statement for healthcare professionals from the Committee on Rheu- Failure modes in conservative and surgical management of infectious
matic Fever, Endocarditis, and Kawasaki Disease, Council on Cardio- spondylodiscitis. Eur Spine J 2013; 22:1837–44.
vascular Disease in the Young, and the Councils on Clinical 141. Kulowski J. The Orr treatment of pyogenic osteomyelitis. Ann Surg
Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, 1936; 103:613–24.
American Heart Association: endorsed by the Infectious Diseases So- 142. Carragee EJ. Pyogenic vertebral osteomyelitis. J Bone Joint Surg Am
ciety of America. Circulation 2005; 111:e394–434. 1997; 79:874–80.
125. Graninger W, Ragette R. Nosocomial bacteremia due to Enterococcus 143. Nolla JM, Ariza J, Gomez-Vaquero C, et al. Spontaneous pyogenic ver-
faecalis without endocarditis. Clin Infect Dis 1992; 15:49–57. tebral osteomyelitis in nondrug users. Semin Arthritis Rheum 2002;
126. Tice AD, Rehm SJ, Dalovisio JR, et al. Practice guidelines for outpatient 31:271–8.
parenteral antimicrobial therapy. IDSA guidelines. Clin Infect Dis 144. Wang Q, Babyn P, Branson H, Tran D, Davila J, Mueller EL. Utility of
2004; 38:1651–72. MRI in the follow-up of pyogenic spinal infection in children. Pediatr
127. Bernard L, Dinh A, Ghout I, et al. Antibiotic treatment for 6 weeks Radiol 2010; 40:118–30.
versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an 145. Carragee EJ. Instrumentation of the infected and unstable spine: a re-
open-label, non-inferiority, randomised, controlled trial. Lancet view of 17 cases from the thoracic and lumbar spine with pyogenic in-
2015; 385:875–82. fections. J Spinal Disord 1997; 10:317–24.
128. Legrand E, Flipo RM, Guggenbuhl P, et al. Management of nontuber- 146. Solis Garcia del Pozo J, Vives Soto M, Solera J. Vertebral osteomyelitis:
culous infectious discitis. treatments used in 110 patients admitted to long-term disability assessment and prognostic factors. J Infect 2007;
12 teaching hospitals in France. Joint Bone Spine 2001; 68:504–9. 54:129–34.
129. Roblot F, Besnier JM, Juhel L, et al. Optimal duration of antibiotic ther- 147. O’Daly BJ, Morris SF, O’Rourke SK. Long-term functional outcome in